XML 45 R30.htm IDEA: XBRL DOCUMENT
v3.25.2

FAIR VALUE MEASUREMENTS (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2025
FAIR VALUE MEASUREMENTS |
Schedule of significant unobservable inputs | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | June 30, 2025
​ |  | Fair Value | ​ |  | Level 1 | ​ | Level 2 | ​ | Level 3
Financial assets: |  | ​ | ​ | ​ |  | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Cash and cash equivalents: |  | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
U.S. treasury notes | ​ | $ | 12,521 | ​ |  | $ | — | ​ | $ | 12,521 | ​ | $ | —
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Total financial assets | ​ | $ | 12,521 | ​ | ​ | $ | — | ​ | $ | 12,521 | ​ | $ | —
​ |  | ​ | ​ | ​ |  | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Financial liabilities: |  | ​ | ​ | ​ |  | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Orbimed Warrant liability | ​ | ​ | 43 | ​ |  | ​ | — | ​ | ​ | — | ​ | ​ | 43
Pre-Funded Warrant liability | ​ | ​ | 3,350 | ​ | ​ | ​ | — | ​ | ​ | 3,350 | ​ | ​ | —
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Total financial liabilities | ​ | $ | 3,393 | ​ | ​ | $ | — | ​ | $ | 3,350 | ​ | $ | 43
​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | December 31, 2024
​ |  | Fair Value | ​ |  | Level 1 | ​ | Level 2 | ​ | Level 3
Financial assets: |  | ​ | ​ | ​ |  | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Cash and cash equivalents: |  | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
U.S. treasury notes | ​ | $ | 7,305 | ​ |  | $ | — | ​ | $ | 7,305 | ​ | $ | —
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Total financial assets | ​ | $ | 7,305 | ​ | ​ | $ | — | ​ | $ | 7,305 | ​ | $ | —
​ |  | ​ | ​ | ​ |  | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Financial liabilities: |  | ​ | ​ | ​ |  | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Long-term loan |  | $ | 28,923 | ​ |  | $ | — | ​ | $ | — | ​ | $ | 28,923
Orbimed Warrant liability | ​ | ​ | 72 | ​ |  | ​ | — | ​ | ​ | — | ​ | ​ | 72
Pre-Funded Warrant liability | ​ | ​ | 5,896 | ​ |  | ​ | — | ​ | ​ | 5,896 | ​ | ​ | —
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Total financial liabilities | ​ | $ | 34,891 | ​ | ​ | $ | — | ​ | $ | 5,896 | ​ | $ | 28,995
Schedule of summary of change in fair value of liabilities | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | Long-Term Loan | ​ | ​ | Orbimed Warrant Liability | ​ | ​ | Pre-funded Warrant Liability
Balance as of March 31, 2025 | ​ | $ | 29,194 | ​ | $ | 42 | ​ | $ | 3,061
Exercise | ​ | ​ | — | ​ | ​ | — |  |  | —
Principal repayments on long-term loan | ​ | ​ | (31,515) | ​ | ​ | — | ​ | ​ | —
Change in fair value | ​ | ​ | 2,321 | ​ | ​ | 1 | ​ | ​ | 289
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Balance as of June 30, 2025 | ​ | $ | 0 | ​ | $ | 43 | ​ | $ | 3,350
​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | Long-Term Loan | ​ | ​ | Orbimed Warrant Liability | ​ | ​ | Pre-funded Warrant Liability
Balance as of January 1, 2025 | ​ | $ | 28,923 | ​ | $ | 72 | ​ | $ | 5,896
Exercise | ​ | ​ | — | ​ | ​ | — |  |  | (1,750)
Principal repayments on long-term loan | ​ | ​ | (31,515) | ​ | ​ | — | ​ | ​ | —
Change in fair value | ​ | ​ | 2,592 | ​ | ​ | (29) | ​ | ​ | (796)
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Balance as of June 30, 2025 | ​ | $ | 0 | ​ | $ | 43 | ​ | $ | 3,350
​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | Long-Term Loan | ​ | ​ | Orbimed Warrant Liability | ​ | ​ | Pre-funded Warrant Liability
Balance as of March 31, 2024 | ​ | $ | 28,462 | ​ | $ | 215 | ​ | $ | 15,301
Issuance | ​ | ​ | — | ​ | ​ | — |  | ​ | —
Change in fair value | ​ | ​ | 169 | ​ | ​ | (61) | ​ | ​ | (3,401)
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Balance as of June 30, 2024 | ​ | $ | 28,631 | ​ | $ | 154 | ​ | $ | 11,900
​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | Long-Term Loan | ​ | ​ | Orbimed Warrant Liability | ​ | ​ | Pre-funded Warrant Liability
Balance as of January 1, 2024 | ​ | $ | 28,545 | ​ | $ | 240 | ​ | $ | —
Issuance | ​ | ​ | — | ​ | ​ | — |  | ​ | 24,457
Change in fair value | ​ | ​ | 86 | ​ | ​ | (86) | ​ | ​ | (12,557)
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Balance as of June 30, 2024 | ​ | $ | 28,631 | ​ | $ | 154 | ​ | $ | 11,900
​
Warrant Liability |
FAIR VALUE MEASUREMENTS |
Schedule of significant unobservable inputs | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | June 30, | ​ | December 31,
​ | ​ | 2025 | ​ | 2024
Stock price | ​ | $ | 0.67 | ​ |  | $ | 0.79 | ​
Exercise price | ​ | ​ | 4.00 | ​ | ​ | ​ | 4.00 | ​
Expected term (in years) | ​ | ​ | 3.95 | ​ | ​ | ​ | 4.44 | ​
Volatility | ​ | ​ | 86.4% | ​ | ​ | ​ | 91.2% | ​
Dividend rate | ​ | ​ | — | ​ | ​ | ​ | — | ​
Risk-free interest rate | ​ | ​ | 3.71% | ​ | ​ | ​ | 4.53% | ​

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 + Details
Name: | us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details
Name: | us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details
Name: | us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_FairValueByLiabilityClassAxis=drio_WarrantLiabilityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |